Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Paul Martini Prize for therapeutic vaccinations against brain tumors

© Paul-Martini-Stiftung

On April 15, neurologist Michael Platten was awarded the Paul Martini Prize 2024. He received the prize for the development of therapeutic vaccines against malignant brain tumors. The prize is awarded annually by the Paul Martini Foundation, Berlin, for outstanding achievements in clinical-therapeutic drug research.

ERC Advanced Grants for Michael Platten

The European Research Council (ERC) supports visionary, ground-breaking research projects with its "Advanced Grants". This year, the Council awarded the prestigious funding to two researchers at the German Cancer Research Center (DKFZ): Neuroscientist Hannah Monyer, DKFZ and Heidelberg University Hospital, wants to find new explanations for the development of neurodegenerative diseases. Neurologist Michael Platten, DKFZ and University Medical Center Mannheim, will use the ERC funding to develop and test personalized cellular immunotherapies against malignant brain tumors.


Press release

Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies


Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system. In this way, the body presumably curbs destructive immune reactions. Researchers from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors (ICI) in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. Interventions in this mechanism could potentially improve the efficacy of these cellular cancer immunotherapies.


Press release

Machine learning classifier accelerates the development of cellular immunotherapies


Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.


Press release

A H3K27M-targeted vaccine in adults with diffuse midline glioma


Diffuse midline gliomas are higly aggressive primary central nervous system tumors in children and young adults that are characterized by the clonal driver mutation H3 K27M. Scientists and clinicians from the Platten lab have developed a peptide vaccine that sucessfully elicits tumor specific immune responses against this mutation in the majority of adult patients with relaps tumors. Since mutated peptides are presented on the surface of the tumor cells these findings stir up hope that diffuse midline glioma is amenable to immunotherapy with peptide vaccination. The peptide vaccine is now tested in the INTERCEPT H3 phase 1 clinical trial together with immune checkpoint inhibition in patients with newly diagnosed diffuse midline glioma.



NLGN4X TCR transgenic T cells to treat gliomas


Neuroligin 4 X-linked (NLGN4X) harbors a human leukocyte antigen (HLA)-A2-restricted tumor-associated antigen, overexpressed in human gliomas, that was found to induce specific cytotoxic T cell responses following multi-peptide vaccination in patients with newly- diagnosed glioblastoma.
Here we showed that, an HLA-A *02-restricted vaccine-induced T cell receptor specifically binding NLGN4X131-139 was applied for therapeutic use. Reactivity, cytotoxicity, and polyfunctionality of this NLGN4X-specific TCR is demonstrated in various cellular models. Intracerebroventricular administration of NLGN4X-TCR-T prolongs survival and leads to an objective response rate (ORR) of 44.4 % in experimental gliomas-bearing NSG MHC I/II KO mice compared to 0.0 % in control groups, respectively.
Concluding that NLGN4X-TCR-T demonstrates efficacy in a preclinical glioblastoma model. On a global scale, we provide first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.



Twelve times top class in citations


Twelve scientists who conduct research at the DKFZ or head joint bridging departments with the DKFZ made it to the very top in 2023: they are among the top one percent of the world's most cited researchers in their respective fields. Scientists whose work is cited particularly frequently by peers are considered to have above-average recognition in their field. The frequency of citations is therefore one of the most important measures of the influence and performance of individual researchers.


To press release

New PhDs after brilliant defenses!


Congratulations to Alice!


Congratulations to Khwab!


Congratulations to Katharina!

What keeps the immune defense in brain tumors functional


Brain tumors are characterized by a distinct immunosuppressive microenvironment, leading to failure of novel immunotherapeutic approaches. Scientists from the team of Prof. Platten have now shown how the intratumoral antigen presentation via MHC class II can determine the fate and anti-tumor function of cytotoxic CD8 T cells in brain tumors. In patient material and preclinical models, the researchers showed that the immunosuppressive molecule Osteopontin is produced in large amounts in tumors absent of MHC class II and that restoration of the antigen presentation via MHC class II leads to reduced Osteopontin levels and thus restored CD8 T cell function.

to press release

Lukas Bunse is awarded with the Hella Bühler prize

© Tobias Schwerdt

Lukas Bunse from the German Cancer Research Center in Heidelberg and the University Hospital Mannheim received the Hella Bühler prize that he was awarded with in 2019. The award is given out by Heidelberg University and is aimed at young researchers who have conducted studies from outstanding quality in the field of cancer research. The prize named after Dr. Hella Bühler comprises 100.000 € intended to supply the scientist's further research projects in this field.

Press relase link:

Vaccination against mutated protein first tested in brain tumor patients


Cancer vaccines can support the body's own immune system to fight a tumor. Since mutations in tumor cells often lead to specifically altered proteins, a vaccine can boost the immune system to recognize such mutated proteins. Scientists and clinicians around Prof. Michael Platten and within the German Cancer Consortium DKTK and the German Neurooncology Working Group NOA for the first time have tested a mutation-specific vaccine targeting a glioma driver mutation in the IDH1 protein in malignant brain tumor patients in a phase 1 clinical study. They demonstrate not only safety and immunogenicity of the vaccine, but also show enhanced local immune reactions and IDH1 mutant-specific activated T cells within the tissue after vaccination. (Platten et al. Nature 2021 als link zu

To press release als link zu (in German only)

Experimental glioma model reveals novel approach for immunotherapy in glioblastoma patients

© Fotolia

Malignant brain tumors, such as glioblastomas are frequently resistant to immunotherapies. Scientists from Prof. Dr. Michael Platten's lab at the German Cancer Research Center and Mannheim University Hospital were able to identifiy a mechanism of restistance to immune checkpoint blockade in a mouse model of glioma. (Katrin Aslan, et al. Nature Communications, 2020)

to press release (in German only)

Michael Platten among the most highly cited researchers worldwide


Nine researchers at dkfz are among the world's most influential researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations for field and year. Michael Platten is included in this ranking of "Highly Cited Researchers" in the "cross-field" category.

to press release (in German only) 


Lukas Bunse receives award for the development of cellular therapies

© Uwe Anspach/DKFZ

Lukas Bunse from the German Cancer Research Center in Heidelberg and the University Hospital Mannheim receives this year's Swiss Bridge award. Bunse shares the award with a Swiss scientist. Both of them receive 250,000 Swiss francs for the implementation of their research projects.

to press release (in German only) 


Together against glioma - DKFZ part of new CRC

© P. Kickingereder / University Hospital Heidelberg

With Collaborative Research Centres (CRCs), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) allows researchers to tackle innovative, challenging, complex and long-term research undertakings through the coordination and concentration of individuals and resources within the applicant universities. The new CRC 1389 "Understanding and targeting resistance in glioblastoma – UNITEGLIOBLASTOMA" aims to develop concepts to predict and monitor treatment response and failure, and ultimately, to invent novel therapies for glioblastoma patients.

to press release (in German only) 


German Cancer Award 2019 goes to Michael Platten

Prof. Dieter Saur (Munich), Prof. Michael Platten (Mannheim/Heidelberg), Prof. Ugur Sahin (Mainz) and Prof. Roland Rad (Munich)
© EMBL Photolab

Prof. Dr. Michael Platten has been awarded the German Cancer Award 2019, one of the most prestigious distinctions in cancer medicine in Germany. Prof. Platten receives the award in the category Clinical Research for his work on immunotherapies for glioma, in particular for the discovery and development of a vaccine against IDH1 (isocitrate dehydrogenase 1), a common mutation found in low-grade gliomas. 

to press release (in German only)


Prof. Michael Platten and The Platten Lab are on Twitter

© Twitter

For more up to date information and news, we highly recommend following us on Twitter! 


Follow Prof. Michael Platten on Twitter: @platten_michael


Follow The Platten Lab on Twitter: @Platten_lab


to top
powered by webEdition CMS